Payment overview · 2025
General Payments
$1,058.39
45 reported records · 12 companies
Healthcare provider profile · identity verified
Yanina Etlis, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · REGO PARK, NY · NPI 1730160920
Verified facts
What the public records show
CMS Open Payments records show Yanina Etlis, D.O. received $1,058.39 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $325.70 | 30.8% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $316.19 | 29.9% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $107.02 | 10.1% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $65.82 | 6.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.08 | 5.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.30 | 4.0% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $38.63 | 3.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.96 | 2.7% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.22 | 2.3% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $20.60 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.47 | 1.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.40 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,058.39 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $229.86 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.66 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.93 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $107.02 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $107.02 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $87.65 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $86.33 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $65.82 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $38.63 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 103 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 217 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 216 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
216 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
151 | 30 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
216 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 188 |
| Metoprolol Succinate | Metoprolol Succinate | 668 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 649 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 558 | 126 |
| Losartan Potassium | Losartan Potassium | 505 | 141 |
| Metformin Hcl | Metformin Hcl | 328 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 65 |
| Vascepa | Icosapent Ethyl | 300 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 51 |
| Farxiga | Dapagliflozin Propanediol | 217 | 39 |
| Linzess | Linaclotide | 216 | 39 |
| Alendronate Sodium | Alendronate Sodium | 213 | 41 |
| Eliquis | Apixaban | 190 | 38 |
| Jardiance | Empagliflozin | 179 | 38 |
| Omeprazole | Omeprazole | 176 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 44 |
| Synthroid | Levothyroxine Sodium | 151 | 30 |
| Ozempic | Semaglutide | 150 | 26 |
| Carvedilol | Carvedilol | 147 | 34 |
| Famotidine | Famotidine | 144 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 30 |
| Furosemide | Furosemide | 127 | 29 |
| Gabapentin | Gabapentin | 127 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 27 |
| Ezetimibe | Ezetimibe | 108 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 108 | 16 |
| Metformin Hcl Er | Metformin Hcl | 105 | 30 |
| Glipizide Er | Glipizide | 104 | 20 |
| Creon | Lipase/Protease/Amylase | 103 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 29 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 101 | 19 |
| Lisinopril | Lisinopril | 98 | 27 |
| Mounjaro | Tirzepatide | 96 | 21 |
| Simvastatin | Simvastatin | 95 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 22 |
| Myrbetriq | Mirabegron | 86 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 80 | 17 |
| Dexilant | Dexlansoprazole | 77 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 76 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 13 |
| Enalapril Maleate | Enalapril Maleate | 67 | 15 |
| Atenolol | Atenolol | 62 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 62 | 20 |
| Ranolazine Er | Ranolazine | 61 | suppressed |
| Rybelsus | Semaglutide | 56 | suppressed |
| Nifedipine Er | Nifedipine | 53 | 11 |
| Allopurinol | Allopurinol | 52 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 51 | suppressed |
| Finasteride | Finasteride | 49 | 11 |
| Montelukast Sodium | Montelukast Sodium | 48 | 12 |
| Glipizide | Glipizide | 46 | 13 |
| Mirtazapine | Mirtazapine | 45 | 14 |
| Spironolactone | Spironolactone | 45 | 12 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 13 |
| Azelastine Hcl | Azelastine Hcl | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Repaglinide | Repaglinide | 43 | 13 |
| Ammonium Lactate | Ammonium Lactate | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 41 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Valsartan | Valsartan | 38 | 12 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 34 | suppressed |
| Prolia | Denosumab | 33 | 19 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Livalo | Pitavastatin Calcium | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 31 | 12 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Multaq | Dronedarone Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lipitor | Atorvastatin Calcium | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Glipizide Xl | Glipizide | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paricalcitol | Paricalcitol | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Ztlido | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,058.39 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Arikayce, BREZTRI, CAMZYOS, CONTRAVE, CREON, ECC Solutions, ELIQUIS, EVENITY, FARXIGA, GEMTESA, IBSRELA, LINZESS, NURTEC ODT, PROLIA, QULIPTA, SHINGRIX, UBRELVY | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error